Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients
- 1 February 2001
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 4 (1), 22-28
- https://doi.org/10.1054/drup.2001.0180
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityThe Journal of Experimental Medicine, 1999
- Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon α therapy?Leukemia, 1998
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Bone marrow transplantation for chronic myelogenous leukemiaCurrent Opinion in Oncology, 1992
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Structural organization of the bcr gene and its role in the Ph′ translocationNature, 1985
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985